scholarly journals The connection between hospital mortality and inflamation markers in COVID-19 patients and ischaemic heart disease

2021 ◽  
Vol 25 (3 (99)) ◽  
pp. 118-123
Author(s):  
V. Tashchuk ◽  
R. Nesterovska ◽  
V. Kalarash
Keyword(s):  
Heart Disease ◽  
Inflammatory Response ◽  
Hospital Mortality ◽  
Systemic Inflammation ◽  
Cardiovascular Complications ◽  
Total Blood ◽  
Cell Content ◽  
Heart Damage ◽  
Coronary Atherosclerotic Plaque ◽  
Index Index

The purpose of the work to investigate the connection between hospital mortality and markers of systemic inflammation in COVID-19 patients with ischemic heart disease (IHD).Material and methods. The data of 52 patients’cases of diseases on COVID-19 with IHD who underwent inpatient treatment were analyzed. The first group included 40 patients who were discharged with recovery, and the second group included 12 patients who died. The degree of systemic inflammation syndrome in the selected groups of patients was estimated by the number of leukocytes and cellular composition of peripheral blood upon admission to the hospital, and based on the data received, the value of hematological integral indices was calculated.Results. It has been established that group II patients who died of cardiovascular complications connected with COVID-19 had significantly higher levels of systemic inflammatory response, which exhibits a significant increase in the total blood white blood cell content and increases in the percentage of neutrophils with a decrease in the percentage of lymphocytes and is substantially higher than the integrated haematological indices: leukocyte shift index, index of the ratio of neutrophils to lymphocytes and index of the ratio of neutrophils to monocytes. During the systemic inflammatory reaction, it has been observed that the inflammatory process aggravates the coronary atherosclerotic plaque making them more susceptible to rupture. Therefore, we can assume that existing IHD combined with an enhanced inflammatory response can lead to heart damage in patients infected with SARS-CoV- 2.Conclusion. Lymphocytopenia, excessive activation of the inflammatory cascade and heart damage are important features of COVID-19 disease and have high predictive value.

scholarly journals Heart ultrasound in COVID-19

2020 ◽  
Vol 26 (3) ◽  
pp. 270-276
Author(s):  
O. N. Dzhioeva ◽  
O. M. Drapkina
Keyword(s):  
Heart Disease ◽  
Cardiac Arrhythmias ◽  
Myocardial Injury ◽  
Cardiovascular Complications ◽  
Diagnostic Methods ◽  
Suspected Infection ◽  
Heart Damage ◽  
Acute Myocardial Injury ◽  
Diagnostic Role ◽  
Coronavirus Infection

Given the risk of cardiovascular complications in COVID-19, including exacerbation of pre-existing heart disease, acute myocardial injury, and drug-related cardiac arrhythmias, echocardiography (ECHO) is one of the main diagnostic methods for examining patients with suspected infection or confirmed disease. The article presents the main statements regarding transthoracic ECHO during a pandemic. The main issues related to the FOCUS ECHO are described, as it may play important diagnostic role in case of suspected myocarditis, which can be one of the manifestations of heart damage of coronavirus infection.

scholarly journals Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score

2021 ◽  
Vol 9 (3) ◽  
pp. e002277 ◽  
Author(s):  
Gino M Dettorre ◽  
Saoirse Dolly ◽  
Angela Loizidou ◽  
John Chester ◽  
Amanda Jackson ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Cancer Progression ◽  
Systemic Inflammation ◽  
Prognostic Score ◽  
Prognostic Index ◽  
Glasgow Prognostic Score ◽  
Prognostic Nutritional Index ◽  
Adverse Outcomes ◽  
Patients With Cancer ◽  
Inflammatory Score

BackgroundPatients with cancer are particularly susceptible to SARS-CoV-2 infection. The systemic inflammatory response is a pathogenic mechanism shared by cancer progression and COVID-19. We investigated systemic inflammation as a driver of severity and mortality from COVID-19, evaluating the prognostic role of commonly used inflammatory indices in SARS-CoV-2-infected patients with cancer accrued to the OnCovid study.MethodsIn a multicenter cohort of SARS-CoV-2-infected patients with cancer in Europe, we evaluated dynamic changes in neutrophil:lymphocyte ratio (NLR); platelet:lymphocyte ratio (PLR); Prognostic Nutritional Index (PNI), renamed the OnCovid Inflammatory Score (OIS); modified Glasgow Prognostic Score (mGPS); and Prognostic Index (PI) in relation to oncological and COVID-19 infection features, testing their prognostic potential in independent training (n=529) and validation (n=542) sets.ResultsWe evaluated 1071 eligible patients, of which 625 (58.3%) were men, and 420 were patients with malignancy in advanced stage (39.2%), most commonly genitourinary (n=216, 20.2%). 844 (78.8%) had ≥1 comorbidity and 754 (70.4%) had ≥1 COVID-19 complication. NLR, OIS, and mGPS worsened at COVID-19 diagnosis compared with pre-COVID-19 measurement (p<0.01), recovering in survivors to pre-COVID-19 levels. Patients in poorer risk categories for each index except the PLR exhibited higher mortality rates (p<0.001) and shorter median overall survival in the training and validation sets (p<0.01). Multivariable analyses revealed the OIS to be most independently predictive of survival (validation set HR 2.48, 95% CI 1.47 to 4.20, p=0.001; adjusted concordance index score 0.611).ConclusionsSystemic inflammation is a validated prognostic domain in SARS-CoV-2-infected patients with cancer and can be used as a bedside predictor of adverse outcome. Lymphocytopenia and hypoalbuminemia as computed by the OIS are independently predictive of severe COVID-19, supporting their use for risk stratification. Reversal of the COVID-19-induced proinflammatory state is a putative therapeutic strategy in patients with cancer.

scholarly journals Systemic inflammation induces release of cell-free DNA from hematopoietic and parenchymal cells in mice and humans

2019 ◽  
Vol 3 (5) ◽  
pp. 724-728 ◽  
Author(s):  
Anne Jan van der Meer ◽  
Anna Kroeze ◽  
Arie J. Hoogendijk ◽  
Aicha Ait Soussan ◽  
C. Ellen van der Schoot ◽  
...  
Keyword(s):  
Inflammatory Response ◽  
Systemic Inflammation ◽  
Hematopoietic Cells ◽  
Systemic Inflammatory Response ◽  
Cell Free Dna ◽  
Free Dna ◽  
Key Points ◽  
Parenchymal Cells

Key PointsDuring a systemic inflammatory response, cell-free DNA is first released by hematopoietic cells and thereafter by nonhematopoietic cells.

scholarly journals Risk Prediction of Cardiovascular Complications in Pregnant Women With Heart Disease

2016 ◽  
Author(s):  
Luciana Carvalho Martins ◽  
Claudia Maria Vilas Freire ◽  
Carolina Andrade Bragança Capuruçu ◽  
Maria do Carmo Pereira Nunes ◽  
Cezar Alencar de Lima Rezende
Keyword(s):  
Heart Disease ◽  
Pregnant Women ◽  
Risk Prediction ◽  
Cardiovascular Complications

scholarly journals Association between the level of plasma B-type natriuretic peptide and in-hospital mortality in patients with acute exacerbation of COPD without a history of coronary ischemic heart disease: a retrospective study

2021 ◽  
Author(s):  
Jiyun Cui ◽  
Jie Liu ◽  
Jing Wang ◽  
Meng Lv ◽  
Chunyan Xing ◽  
...  
Keyword(s):  
Mechanical Ventilation ◽  
Heart Disease ◽  
Hospital Mortality ◽  
Ischemic Heart Disease ◽  
Natriuretic Peptide ◽  
Invasive Mechanical Ventilation ◽  
Ischemic Heart ◽  
Composite Outcome ◽  
History Of ◽  
Secondary Outcomes

Abstract Background: Previous studies suggested that plasma B-type natriuretic peptide (BNP) level was often elevated in patients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) and was associated with increased mortality. However, most studies did not consider the fact that conditions such as coronary ischemic heart disease can also increase BNP level. Therefore, we aimed to explore the association between BNP level and in-hospital mortality in patients with AECOPD without a history of coronary ischemic heart disease.Methods: In this retrospective cohort study, patients who were diagnosed with AECOPD using International Statistical Classification of Diseases and Related Health Problems, Nineth Revision (ICD-9 codes) between January 2017 and December 2019. All data were obtained from electronic patient files and medical data intelligence platform of Jinan Central Hospital. BNP level was determined within 24 hours after admission, and the value was log2 transformed. The primary outcome was in-hospital mortality, and the secondary outcome was a composite outcome of in-hospital mortality or invasive mechanical ventilation.Results: A total of 300 patients were included in this study. Univariate cox regression analysis showed that the unadjusted HRs of the primary and secondary outcomes were 1.85 (95% CI, 1.39-2.47) and 1.45 (95% CI, 1.20-1.75), respectively. After adjustment for age, sex, past medical history, smoking status, drinking status, CURB65 (Confusion, Urea > 7mmol/L, Respiratory rate≥30/min, Blood pressure systolic < 90 mmHg or diastolic <60 mmHg and age > 65 years), arterial partial pressure of O2(PaO2), the adjusted HRs of the primary and secondary outcomes were 3.65 (95% CI, 2.54-5.26) and 1.43 (95% CI, 1.14-1.97), respectively. The results of subgroup analysis by age, sex, and lung function were robust. This study was retrospective, so there was no clinical trial registration.Conclusions: The plasma log2BNP level was significantly associated with in-hospital mortality and a composite outcome of in-hospital mortality or invasive mechanical ventilation.

scholarly journals Psoriasis and Atherosclerosis—Skin, Joints and Cardiovascular Story of Two Plaques in Relation to the Treatment with Biologics

2021 ◽  
Vol 22 (19) ◽  
pp. 10402
Author(s):  
Karina Wierzbowska-Drabik ◽  
Aleksandra Lesiak ◽  
Małgorzata Skibińska ◽  
Michał Niedźwiedź ◽  
Jarosław D. Kasprzak ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Inflammatory Response ◽  
Cardiac Dysfunction ◽  
Cardiovascular Complications ◽  
Systemic Inflammatory Response ◽  
Cardiovascular Safety ◽  
Inflammatory Cascade ◽  
Atherosclerosis Progression ◽  
Tnf Α

It is known that both psoriasis (PSO) limited to the skin and psoriatic arthritis (PSA) increase the risk of cardiovascular complications and atherosclerosis progression by inducing systemic inflammatory response. In recent decades, the introduction of biological medications directed initially against TNF-α and, later, different targets in the inflammatory cascade brought a significant breakthrough in the efficacy of PSO/PSA treatment. In this review, we present and discuss the most recent findings related to the interplay between the genetics and immunology mechanisms involved in PSO and PSA, atherosclerosis and the development of cardiac dysfunction, as well as the current PSO/PSA treatment in view of cardiovascular safety and prognosis.

scholarly journals COVID-19 Induced Cardiovascular Complications and Recent Therapeutic Advances

2021 ◽  
Vol 3 (6) ◽  
pp. 17-22
Author(s):  
Selia Chowdhury ◽  
Mehedi Hasan Bappy ◽  
Samia Chowdhury ◽  
Md. Shahraj Chowdhury ◽  
Nurjahan Shipa Chowdhury
Keyword(s):  
Heart Failure ◽  
Pulmonary Hypertension ◽  
Heart Disease ◽  
Pericardial Effusion ◽  
Ventricular Arrhythmias ◽  
Cardiovascular Complications ◽  
Inflammatory Heart Disease ◽  
Global Pandemic ◽  
The World ◽  
Therapeutic Measures

A global pandemic instigated by SARS-CoV-2 virus has been going strongly for almost two years. There have been almost 240 million cases with almost 5 million fatalities all over the world so far. COVID has affected almost every aspect of people’s lives halting the world in immeasurable ways. Although COVID-19 is mostly affecting the respiratory system, it is also responsible for a significant amount of cardiovascular system involvement. On one hand, it deteriorates any pre-existing cardiovascular condition, on another hand, it triggers other inflammation-facilitated acute events. They comprise of inflammatory heart disease, severe pericardial effusion, ventricular arrhythmias, endothelial dysfunction, pulmonary hypertension, heart failure, and many more. In this article, we summarize the features, management, and treatment of several important COVID-19 induced cardiovascular complications. Recent advances in the treatment of these diseases along with the justification and concerns of specific therapeutic measures are also discussed.

Abstract P075: Influence of Systemic Interleukin-6 on the Inverse Association between Your-Choice American Heart Diet and a 41-Year Mortality Risk from Coronary Heart Disease among Men

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Jun Dai ◽  
Anthony J Acton ◽  
Robert V Considine ◽  
Ruth E Krasnow ◽  
Terry Reed
Keyword(s):  
Coronary Heart Disease ◽  
Heart Disease ◽  
Systemic Inflammation ◽  
Mortality Risk ◽  
Interleukin 6 ◽  
Reactive Protein ◽  
Chd Risk ◽  
Long Term Mortality

Introduction: Whole diet evaluated using dietary pattern is associated with systemic inflammation and coronary heart disease (CHD). Systemic inflammation also contributes to CHD risk. Genetic factors explain variations in whole diet, systemic inflammation, and CHD. However, it is unknown whether systemic inflammation is a mechanism linking whole diet to the long-term mortality risk from coronary heart disease independent of genes. Hypothesis: Systemic inflammation measured as plasma interleukin-6 levels medicates the association between whole diet and long-term mortality risk from coronary heart disease independent of genes. Methods: From the National Heart, Lung, and Blood Institute Twin Study, we included 554 white, middle-aged, veteran male twins (105 monozygotic and 109 dizygotic twin pairs; 65 monozygotic and 61 dizygotic unpaired twins). The twins were not on antihypertensive medication and had diastolic blood pressure below 105 mmHg at baseline (1969-1973) and did not have suspected acute inflammation [plasma levels of interleukin-6 (IL-6) above 10 pg/mL or C-reactive protein above 30 mg/L)]. Usual dietary data at baseline were collected through nutritionist-administered dietary history interview. Your-Choice American Heart Diet (YCARD) score was devised to quantitatively evaluate whole diet. Plasma interleukin-6 and C-reactive protein levels were measured with ELISA. Data on vital status and death causes were collected through death certificates until Dec 31, 2010. A frailty survival model was used to estimate various associations: overall (equivalent to the association in the general population), within-pair (independent of genes and environment common to co-twins), and between-pair (indicating influence of the common factors). We controlled for total caloric intake and known CHD risk factors including body mass index and modified Framingham Risk Score. Results: There were 75 CHD deaths during a 41-year follow-up (median follow-up of 34 years). The adjusted overall association between YCARD score and the CHD mortality risk was negative [partial coefficient for a 10-unit increment in the YCARD score: βo (95% confidence interval (CI)): -0.13 (-0.24, -0.02); hazard ratio (95% CI): 0.88 (0.78, 0.98)]. The partial regression coefficient was -0.02 [95% CI (-0.23, 0.19)] for the within-pair effect of YCARD (βw) and -0.12 [95% CI (-0.26, 0)] for the between-pair effect of YCARD (βb) in relation to CHD mortality risk. Additional adjustment for IL-6 led to a 15.4% reduction in the βo, a 100% increment in the βw, and a 16.7% reduction in the βb. Conclusions: Systemic inflammation measured as interleukin-6 mediates the association between whole diet and long-term coronary heart mortality risk, which is largely through genetic and environmental factors shared between co-twins.

Cardiovascular complications of novel multiple myeloma treatments

ESC CardioMed ◽  
2018 ◽  
pp. 1176-1178
Author(s):  
Daniel J. Lenihan
Keyword(s):  
Heart Failure ◽  
Multiple Myeloma ◽  
Heart Disease ◽  
Early Detection ◽  
Antithrombotic Therapy ◽  
Cardiovascular Events ◽  
Cardiovascular Complications ◽  
Novel Therapies ◽  
Cardiac Events ◽  
Increased Risk

The treatment of multiple myeloma has dramatically changed in the last decade. Novel therapies have had an important impact on the overall outcome for patients but are associated with important cardiovascular events. There is certainly concern about the development of heart failure but also treatment-induced hypertension and a known increased risk of thrombotic events, including ischaemic heart disease. The management of these cardiac events includes prevention, early detection, and optimal treatment with antithrombotic therapy as well as medical therapy for heart failure.

Sign in / Sign up

Export Citation Format

Share Document